LC16m8

References in periodicals archive ?

As important, the LC16m8 vaccine produced minimal local reactions and no severe adverse events, said Dr.

The researchers noted that while the total sample size in the study limited their ability to "conclusively confirm the absence of severe adverse events," their results support the conclusion that LC16m8 "causes minimal local manifestations and systemic adverse effects."

New smallpox vaccine immunogenic and safe

The third-generation smallpox vaccine LC16m8 was found to be as immunogenic as existing smallpox vaccines but appeared to be safer, according to a study of over 3,000 Japanese adults.

The five, attenuated, tissue-cultured LC16m8 vaccine proved to be immunogenic in adults who had never received any smallpox vaccination, and it also produced an adequate booster response in those who had been vaccinated previously.

They assessed the LC16m8 vaccine in healthy personnel in the Japan Self-Defense Forces inoculated in 2002-2005.

The researchers noted that while the total sample size in the study limited their ability to "conclusively confirm that absence of severe adverse events," their results support the conclusion that LC16m8 "causes minimal local manifestations and systemic adverse effects."

New smallpox vaccine found immunogenic

They gave single shots of the LC16m8 vaccine--which uses a live, attenuated virus--to 3,221 participants from the Japan Self-Defense Forces between 2002 and 2005, wrote the researchers, led by Tomoya Saito of Keio University in Tokyo.

A smallpox vaccine appears to be effective in a trial in Japan, with none of the serious side effects that are linked to earlier tests, researchers said

LC16m8, an attenuated VACV strain developed by Japan in 1975 for primary vaccination, was derived by passing the Lister strain 36 times through primary rabbit kidney cells at low temperature (30 [degrees] C) (36).

Developing new smallpox vaccines. (Perspectives)

Medical browser ?

Full browser ?